215 related articles for article (PubMed ID: 10824041)
41. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae.
Waites KB; Crabb DM; Duffy LB
Int J Antimicrob Agents; 2003 Jun; 21(6):574-7. PubMed ID: 12791472
[TBL] [Abstract][Full Text] [Related]
42. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Jorgensen JH; Weigel LM; Swenson JM; Whitney CG; Ferraro MJ; Tenover FC
Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
[TBL] [Abstract][Full Text] [Related]
43. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):323-6. PubMed ID: 12151195
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Bédos JP; Rieux V; Bauchet J; Muffat-Joly M; Carbon C; Azoulay-Dupuis E
Antimicrob Agents Chemother; 1998 Apr; 42(4):862-7. PubMed ID: 9559797
[TBL] [Abstract][Full Text] [Related]
46. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Moine P; Cherbuliez C; Peytavin G; Fantin B; Köhler T
Antimicrob Agents Chemother; 2005 Mar; 49(3):1046-54. PubMed ID: 15728901
[TBL] [Abstract][Full Text] [Related]
47. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
[TBL] [Abstract][Full Text] [Related]
48. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
49. Bactericidal activity of trovafloxacin (CP-99,219).
Morrissey I
J Antimicrob Chemother; 1996 Dec; 38(6):1061-6. PubMed ID: 9023654
[TBL] [Abstract][Full Text] [Related]
50. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis.
Mortensen JE; Rodgers GL
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():47-9. PubMed ID: 10824032
[TBL] [Abstract][Full Text] [Related]
51. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Pankuch GA; Dewasse BE; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
[TBL] [Abstract][Full Text] [Related]
52. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae.
Klugman KP; Gootz TD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():51-5. PubMed ID: 9222070
[TBL] [Abstract][Full Text] [Related]
53. Activity of gemifloxacin against invasive and multi-resistant Streptococcus pneumoniae isolates collected in the UK.
Johnson AP; Warner M; Nguyen-Van-Tam JS; Livermore DM
J Antimicrob Chemother; 2003 Jan; 51(1):188-90. PubMed ID: 12493813
[No Abstract] [Full Text] [Related]
54. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O
Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
[TBL] [Abstract][Full Text] [Related]
55. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Clark CL; Nagai K; Davies TA; Bozdogan B; Dewasse B; Jacobs MR; Appelbaum PC
Clin Microbiol Infect; 2002 Jun; 8(6):373-80. PubMed ID: 12084107
[TBL] [Abstract][Full Text] [Related]
56. Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.
Malerczyk C; Kolbert M; Kinzig-Schippers M; Sörgel F; Machka K; Shah PM
J Chemother; 2004 Feb; 16(1):56-61. PubMed ID: 15078000
[TBL] [Abstract][Full Text] [Related]
57. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020
[TBL] [Abstract][Full Text] [Related]
58. In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia.
Urbásková P; Trupl J; Hupková H; Appelbaum PC; Jacobs MR
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):686-8. PubMed ID: 8894582
[TBL] [Abstract][Full Text] [Related]
59. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
Thorburn CE; Edwards DI
J Antimicrob Chemother; 2001 Jul; 48(1):15-22. PubMed ID: 11418508
[TBL] [Abstract][Full Text] [Related]
60. Antimicrobial activity of DW286 against Streptococcus pneumoniae.
Park HS; Jung SJ; Choi DR; Kwak JH
Int J Antimicrob Agents; 2010 Sep; 36(3):230-3. PubMed ID: 20627463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
